News

Schrodinger Inc (SDGR) reports robust Q2 2026 with record ACV growth, strategic AI advancements, and raised full-year drug discovery guidance despite margin pressures from hosted transition.

Schrodinger (NASDAQ:SDGR) said second-quarter annual contract value growth accelerated as demand broadened across large pharmaceutical customers, biotechnology companies and materials-science customers, while the company launched early access for Bunsen, its agentic AI co-scientist. Second-quarter

Schrodinger (SDGR) delivered earnings and revenue surprises of +113.33% and +15.58%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

It's been a pretty great week for Schrödinger, Inc. ( NASDAQ:SDGR ) shareholders, with its shares surging 11% to...

Schrödinger (SDGR) is back in focus after first quarter earnings. Revenue held near prior year levels, and sales, net loss and per share figures gave investors fresh data on the company’s current spending profile. See our latest analysis for Schrödinger. The stock has seen an 11.14% 1 month share price return and a 5.15% 7 day share price return. However, the year to date share price return shows a 28.42% decline and the 1 year total shareholder return reflects a 45.37% loss, indicating that...

Moby summary of Schrödinger, Inc.'s Q1 2026 earnings call

Schrodinger (NASDAQ:SDGR) reported first-quarter 2026 results and highlighted progress in its transition to hosted software licensing, growth in annual contract value (ACV), and recent business development activity tied to its drug discovery collaborations. First-quarter metrics and hosted transiti

Schrodinger (SDGR) delivered earnings and revenue surprises of -44.64% and -2.17%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?